In a report released today, Marie Thibault from BTIG maintained a Hold rating on Embecta Corporation (EMBC – Research Report). The company’s shares opened today at $30.80.
Thibault covers the Healthcare sector, focusing on stocks such as Boston Scientific, Masimo, and Abbott Labs. According to TipRanks, Thibault has an average return of 6.8% and a 40.00% success rate on recommended stocks.
Currently, the analyst consensus on Embecta Corporation is a Moderate Sell with an average price target of $28.00.
See today’s best-performing stocks on TipRanks >>
Based on Embecta Corporation’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $274.6 million and a GAAP net loss of $17.2 million. In comparison, last year the company earned a revenue of $300.8 million and had a net profit of $96.9 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
Read More on EMBC:
